A
Alcista
Alcista · 25%PHVS
$32.16
Precio del escenario
$30.680
+0.021 (+0.07%)Al cierre
Loading chart…
- Máximo
- 31.020
- Apertura
- 30.760
- Precio medio ponderado por volumen
- 30.51
- Volumen
- 347.24K
- Capitalización
- 969.24M
- Mínimo
- 29.840
- Importe
- 10.60M
- EV/EBITDA, TTM
- 0.00
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Análisis de IA of Pharvaris NV (PHVS)
ComprarPharvaris NV (PHVS) is a good buy right now due to its recent clinical trial success, which has driven analyst price targets significantly higher, with the average target around $54. Additionally, the stock is currently priced at $27.74, which is well below the lowest analyst target of $40, suggesting substantial upside potential. However, the main risk is the company's ongoing net losses, which amounted to €47.8 million in the last quarter, indicating financial instability that could affect future performance.
Métricas de valoración
El PER previsto actual de Pharvaris NV (PHVS) es 0.00, frente a su media de 5 años de -6.58.
Escenarios de precio de Alphio AI para PHVS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con PHVS en cartera
Cronología de eventos
Noticias
9.509-09NASDAQ.COMPharvaris N.V. Phase 3 Trial Success for Deucrictibant
5.009-09stocktwitsBioCryst's Orladeyo Approved for HAE Attack Prevention
9.509-08stocktwitsRoivant and Pharvaris Achieve Clinical Trial Success
9.509-08Yahoo FinanceBiotech Stocks Hit All-Time Highs Following Positive Trial Results
9.009-08NASDAQ.COMPharvaris Reports Positive Results for HAE Treatment
Preguntas frecuentes sobre PHVS, respondidas por Alphio AI
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet. It operates in the Healthcare sector.
Pharvaris NV (PHVS) is a good buy right now due to its recent clinical trial success, which has driven analyst price targets significantly higher, with the average target around $54. Additionally, the stock is currently priced at $27.74, which is well below the lowest analyst target of $40, suggesting substantial upside potential. However, the main risk is the company's ongoing net losses, which amounted to €47.8 million in the last quarter, indicating financial instability that could affect future performance.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.